Ceribell expands its point-of-care EEG platform with new FDA clearances, delirium reimbursement, and a growing push into bedside brain monitoring.

Samsung and UCSF Neuroscape will test whether Galaxy Watch biometrics can track cognitive change, as wearables move toward brain-health inference.

Aleph Neuro is developing functional ultrasound for non-invasive brain decoding, joining a wider group of companies building around the modality.

BrainsWay and electroCore stand out in a weak year for public neurotech, with strong Q2 revenue growth adding to substantial 2026 share-price gains.

Boston Scientific is expanding neurotech through acquisitions, while Medtronic mixes buyouts, partnerships and investments around an existing portfolio.

Universal Brain’s FDA cleared EEG system adds objective monitoring to psychiatry while pointing toward longer-term treatment-response prediction.

Epitel has raised $26m to expand REMI, a wearable EEG platform designed to extend seizure monitoring across hospitals, homes, and younger patients.

Temple is shifting its wearable patch toward Entropy, a metabolic metric that places it closer to the wider wearables market than the brain.

Preventative scanning is moving into wellness, with MYndspan and Connectome adapting MEG and fNIRS for repeatable, non-diagnostic brain assessments.

Fluent has raised A$2m to develop a subscalp EEG speech interface, with first-in-human studies planned as it tests a less invasive decoding route.

Neuralink completed its first transdural N1 implant, removing a manual dural incision while retaining the craniotomy and wider risks of brain surgery.

Meta’s Brain2Qwerty v2 lifts non-invasive brain-to-text accuracy to 61% from MEG, but bulky scanners and offline decoding still block practical use.

Gestala has raised RMB 570M within six months of launch, and is now expanding its ultrasound BCI platform across Chengdu and Shanghai.

Somareality raised €3M+ to move eye-tracking biomarkers from enterprise settings into cognitive wellness, where signal quality, validation, and platform control remain central questions.

Flourish has raised $500M to build Cortex AI, a brain-inspired system targeting lower-power AI compute. The company enters a crowded biomimetic field without product data or benchmarks.

UNEEG’s FDA clearance brings EpiSight into the US, adding a second implantable continuous EEG system for epilepsy and highlighting the shift from patient logs to longitudinal seizure data.

Samsung’s reported Neuralink chip order connects the BCI company’s next implant generation to a wider Musk manufacturing push across semiconductors, Austin production, and future scale.

Paradromics has implanted Connexus in the first participant in its early feasibility study, testing whether high-bandwidth intracortical BCI can support speech restoration and computer control over time.

Wave Neuroscience has received FDA clearance for MeRT, an EEG-guided TMS system for PTSD. The decision adds to a growing regulatory opening for neuromodulation in psychiatric care.

Oculogica’s SNAP clearance moves eye-tracking concussion assessment into faster sideline workflows, while its age label keeps the first market focused on high school and college sports.

Neuracle and BrainCo are moving toward public listings as Chinese BCI funding accelerates, with large rounds, state backing and different routes into medical, assistive and consumer neurotech markets.

ShiraTronics has completed enrollment in RELIEV-CM2, a pivotal study of its implantable migraine neurostimulator, as regulatory and coding steps begin to shape its path toward FDA review.

Omniscient’s Series D pairs Quicktome expansion with a new CPT code for connectomic analysis, as brain mapping moves from surgical planning tool toward reimbursable clinical workflow.

Pulsetto’s Hackney Half project shows how consumer neurotech is entering running recovery, using VNS, wearables, and case-based data to frame nervous system regulation as a performance layer.

Oura is pairing ring data with cognitive testing and sleep-care pathways, pointing to a clinical-adjacent model built around proxy signals rather than direct neural measurement.

Kariya and NeuraLight are pairing a brain-penetrant GLP-1 program with vision-based biomarkers, as neurodegeneration trials look for better ways to measure functional change.

Prophetic has introduced ultrasound headbands for lucid dreaming, moving an old consumer neurotech idea into focused ultrasound while leaving efficacy and sleep-safety questions unresolved.

Neurovalens received FDA De Novo approval for Modius Spero in PTSD, extending its Modius platform to a fourth indication and strengthening the company’s broader vestibular stimulation thesis.

AMPA’s financing points to a wider shift in MDD neuromodulation, as portable TMS, home-use devices, accelerated protocols, and broader labels begin to reshape how treatment reaches patients.

Neurosoft raised a $7.5M seed round to advance soft cortical BCIs, pairing Swiss neuroengineering roots with US investors, clinical trials, and Science Corp’s BCI infrastructure.

SonoMind raised €20 million to advance a focused ultrasound treatment for depression, testing whether non-invasive deep brain targeting can become a clinical option for treatment-resistant patients.

Motif’s FDA IDE moves its depression implant into first clinical testing, while its MintNeuro partnership highlights the chip-level constraints behind smaller therapeutic BCIs.

Europe’s first Brain Economy Summit framed brain capital as an economic asset. The harder question is whether Europe can turn neuroscience, policy, and funding into scalable systems.

Axoft’s $55M Series A highlights a growing focus on implant materials in BCI, as companies work to improve tissue compatibility, signal quality, and the durability needed for clinical translation.

Sabi has emerged from stealth with a claimed thought-to-text EEG beanie, testing whether high-density sensors and AI can push consumer neurotech beyond metrics and into usable neural input.

April brought a cluster of neural interface updates across cortical, spinal, endovascular, peripheral, and materials-led systems, showing progress beyond a single BCI product model.

INBRAIN has completed enrolment in its first human graphene cortical interface study, adding safety and signal-quality data to its broader push around materials-led BCI development.

Synchron’s INTENT trial marks a new stage in its clinical translation, as the company pairs endovascular BCI development with reimbursement, software, and platform integration work.

CFG’s new white paper signals a more coordinated EU approach to neurotechnology, centered on funding gaps, regulatory clarity, and the unresolved boundary between wellness and medicine.

Epia Neuro has emerged from stealth with a minimally invasive BCI for stroke recovery. Its launch adds to a more active BCI market, where capital and competitive pressure are both rising.

Rune Labs has launched a Parkinson’s AI companion built on years of wearable-derived patient data. The move highlights how cleared neurotech tools can turn clinical monitoring into a longer-term data advantage.

Theta Neuro has raised a $2m pre-seed to advance a wearable EEG patch for seizure prediction. The broader question is whether non-invasive forecasting can become a credible epilepsy product category.

Neurable used EEG-enabled hearing protection to record brain activity during live breaching drills. The dataset points to short-window neural changes that standard post-event assessment can miss.

Cognito’s Ochsner deal sits further along a broader shift in neurotech partnerships, from invasive research sites to translational collaborators and now care-system integration.

The Declaration of Sydney outlines an ethical framework for computational neurosurgery, with wider implications for oversight, enhancement, and neurotech governance.

China’s BCI strategy is starting to produce commercial milestones. A first approved therapeutic device and Gestala’s launch point to a broader competitive field across invasive and non-invasive systems.

Cognito Therapeutics has raised $105 million to advance its gamma-entrainment headset through Phase 3 in Alzheimer’s. The financing sharpens attention on whether biological signals can translate into clinical benefit.

Temple has raised $54 million to build a brain wearable for athletes. The question is whether cerebral hemodynamic sensing can become a useful performance layer.

Science closed an oversubscribed $230M Series C, taking total raised to ~$490M, to commercialize PRIMA in Europe, expand trials into Stargardt and RP, and scale manufacturing and clinical ops in 2026.

Clee Medical raised Seed funding for Neuro Access, an OCT-based tool that brings contrast-free real-time imaging to stereotactic neurosurgery, aiming to reduce uncertainty from brain shift in theatre.